Showing studies related to your query9 results shown

Program Matched

Daraxonrasib

Featured

Revolution Medicines, Inc.

Daraxonrasib (RMC-6236) is Revolution Medicines' investigational oral RAS(ON) multi-selective inhibitor, targeting the active GTP-bound state of RAS across mult…

Pancreatic CancerPancreatic Cancer MetastaticPDAC

Studies (9 shown)

NCT06881784PHASE3RECRUITING

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Sponsor · Revolution Medicines, Inc.Condition · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung CancerIntervention · daraxonrasib, docetaxelUpdated May 2026
NCT07491445PHASE3RECRUITING

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Sponsor · Revolution Medicines, Inc.Condition · Pancreatic Cancer, Pancreatic Cancer MetastaticIntervention · daraxonrasib, gemcitabineUpdated May 2026
NCT07252232PHASE3RECRUITING

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor · Revolution Medicines, Inc.Condition · Pancreatic Cancer, PDACIntervention · daraxonrasibUpdated May 2026
NCT06128551PHASE1, PHASE2RECRUITING

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Sponsor · Revolution Medicines, Inc.Condition · Non-Small Cell Lung Cancer (NSCLC), Colorectal CancerIntervention · Elironrasib, DaraxonrasibUpdated Apr 2026
NCT07573215AVAILABLE

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Sponsor · Revolution Medicines, Inc.Condition · PDAC, PDAC - Pancreatic Ductal AdenocarcinomaIntervention · daraxonrasibUpdated May 2026
NCT07492680PHASE2NOT_YET_RECRUITING

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor · Bristol-Myers SquibbCondition · Solid TumorsIntervention · BMS-986504, DaraxonrasibUpdated May 2026
NCT07397338PHASE1, PHASE2RECRUITING

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Sponsor · Revolution Medicines, Inc.Condition · Advanced Solid Tumors, Metastatic Solid TumorsIntervention · Daraxonrasib, ElironrasibUpdated May 2026
NCT07349537PHASE1RECRUITING

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Sponsor · Revolution Medicines, Inc.Condition · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)Intervention · RMC-5127, daraxonrasibUpdated Feb 2026
NCT06625320PHASE3ACTIVE_NOT_RECRUITING

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor · Revolution Medicines, Inc.Condition · Pancreatic Cancer, PDACIntervention · RMC-6236, GemcitabineUpdated Apr 2026
Showing top 9 results. See all 9 results on CT.gov →